Life Sciences Archive » June, 2018

Life Sciences - June, 2018

327 articles

• Merck Fosamax Appeal Faces Uncertain Odds In High Court
• Justice Kennedy Leaves Mixed Record On Civil Rights
• Drug, Device Cos. Give $8.4B To Docs, Hospitals In 2017
• 2 Firms Seize Spotlight During Sizzling June For IPOs
• CVC Fund Inks €3.03B Deal For Majority Stake In Recordati
• Drug Wholesaler Alleges Pay-For-Delay Scheme By Novartis
• Chancery Fast-Tracks Drug Trial Investor's Fraud Suit
• Split PTAB Panel Agrees To Review Bovine Breeding Patent
• Trump Says He Will Announce Supreme Court Nominee July 9
• Health Hires: Fenwick, Dechert, Holland & Hart, Carlton Fields
• Kennedy's Retirement: Legacy, Fallout & The Battle Ahead
• Pfizer Draws FDA Rebuke Over Estrogen Ring Video
• Actavis Reaches Tentative Deal To Exit Testosterone MDL
• AbbVie, Besins Owe $448M In FTC Androgel Antitrust Case
• Limiting Law Firms' Professional Liability Risks: Part 3
• Dechert Nabs Simpson Thacher IP, Life Sciences Partner
• New Stats On Millennial Attorney Disciplinary Actions
• J&J, Talc Supplier Can't Escape $117M Verdicts In NJ
• A Midyear Review Of State Attorney General Enforcement
• A Cloud On The Horizon: Trade Secret Theft In The Cloud
• Why The Defense Bar Celebrates Kennedy
• UK Watchdog Looks To Revive £89M Drug Pricing Fine
• Roberts Becomes True Power As 'Kennedy Court' Ends
• 'Opioid Babies' Won't Get Own Track In MDL
• $75M Orexigen Asset Sale Gets Approval In Del. Ch. 11
• PE-Backed BJ's Wholesale Club Leads 7 IPOs Totaling $1.7B
• EEOC Says Firing Over Methadone Treatment Flouted ADA
• What High Court Review Of Fosamax Means For Preemption
• Limiting Law Firms' Professional Liability Risks: Part 2
• Fed. Circ. Backs AstraZeneca, Impax Win In Zomig Patent Suit
• Latham, Goodwin Procter Lead $1.3B Biopharma Merger
• Delay On Kennedy Replacement 'Ain't Going To Happen': GOP
• DaVita Hit With $375M Punitive Damages In Colo. Verdict
• Sessions, HHS Unveil $2B Health Care Fraud Takedown
• From Lawmaker To Lawyer: Prioritizing Is Always Key
• Supreme Court Agrees To Review Fosamax MDL Revival
• From Iqbal To Citizens United: Kennedy's Biggest Decisions
• Life After Kennedy: 1 Big Question, 6 Judges To Watch
• Insider Trading Suspect's Son Shouldn't Testify, Judge Says
• 'Goodbye, Tony!' Justices Bid Farewell To Kennedy
• GSK Planned Off-Label Pitch At Every OB-GYN, Families Say
• When Partisan Passion Raged, Kennedy Was The Vote To Get
• Bio-Rad's IP Suit Over DNA Tech Survives Early Win Bids
• Jefferies Seeks Toss Of Failed Biotech Co. Investors' Suit
• Chinese Used-Car Platform Leads 4 IPOs Raising $394M
• DEA Must Release More Distribution Data In Opioid MDL
• Walmart, Glencore Questioned By NY About Pregnancy Bias
• Mylan Urges Full Fed. Circ. To Ax Vanda Drug IP Under Mayo
• Limiting Law Firms' Professional Liability Risks: Part 1
• GOP Kicks Off Race To Confirm Kennedy Replacement
• From Lawmaker To Lawyer: How Congress Affected My Career
• Research Org. Must Pay $3M For Not Filling Up Clinical Trial
• Justice Kennedy's Retirement To Upset High Court Balance
• Theranos Founder's Stay Bid Nixed As Judge Scolds Counsel
• Natera Loses Bid To Toss Illumina DNA Patent Under Mayo
• 7th Circ. Revives Bid To Warn Court Of 'Objector Blackmail'
• DOJ Sets Aside $110M For Native American Crime Victims
• Accountant Hid Silicon Valley VC Firm's $18M Theft, Jury Told
• Pharma, DEA Push To Keep Opioid MDL Data Under Wraps
• Regeneron Told To Pay Merus Atty Fees In Mice Patent Row
• PTAB To Review Columbia DNA Patent, Let School Defend It
• 3rd Circ. Urged To Revive $1M Tax Penalty Case Against CEO
• Deals Rumor Mill: KKR, ConAgra, Spectrum Pharmaceuticals
• Aurobindo Infringing Bladder Drug Patent, Astellas Says
• 4 Opioid Suit Coverage Rulings Attorneys Should Know
• From Lawmaker To Lawyer: DC Isn't As Bad As You Think
• Supreme Court Decision Weakens Deference To Foreign Laws
• Blockchain Technology Can Help Fight Counterfeit Drugs
• Ex-Akebia Statistician Jailed For Speaking To Trial Witness
• Supreme Court Could Clear Up On-Sale Bar In Patent Cases
• Chinese Online Car Marketplace, Biotechs File 6 IPOs
• FDA Clears First Marijuana-Derived Drug
• Express Scripts Limiting Pharmacy Services Market, Suit Says
• Migraine Supplement Co. Denied Fees After Beating IP Suit
• Justices To Weigh Sexual Energy False Ad Class Cert.
• From Lawmaker To Lawyer: 6 Things I Learned In Congress
• High Court To Hear Patent Case Over On-Sale Bar
• Eli Lilly Beats Dr. Reddy's In Cancer Drug Patent Suit
• House Passes Sweeping Opioid Treatment, Medicare Bill
• Feds Can Use 'Material, Nonpublic Info' At Insider Trading Trial
• PTAB Finds Pain Treatment Patent Invalid In PGR
• 14 Firms To Steer IPOs Surpassing $2.5B To Close Busy June
• Health Care Cos. Raise $228M To Cap 10-IPO Week
• Taxation With Representation: Latham, Davis Polk, Stikeman
• FTC, Memory-Booster Co. Spar Over Errors At 2nd. Circ.
• Native American Cases To Watch In The 2nd Half Of 2018
• Celgene Goes After Synthon's Skin Cancer Drug Generic
• Cheers To 80 Years Of The Food, Drug, And Cosmetic Act
• Jones Day Scores IP Tech Pro From McDermott In Chicago
• Drug Patent Challenges At PTAB By The Numbers
• Smith & Nephew Wants Hip MDL Slashed Over Time Bar
• 1st Circ. Upholds Discovery Bid Nix In Gene-Editing IP Row
• FDA Nixes Biosimilar Guidance Over Burden Concerns
• FDA Clarifies Communication Rules For Medical Product Cos.
• Biggest Native American Rulings Of 2018: Midyear Report
• DLA Piper Adds Ex-Morgan Lewis Partner In NJ
• BigLaw's Associate Salary Model Is A Relic Of A Bygone Era
• Plaintiffs' Firm Pulled Into Cahill Asbestos Suit Discovery War
• Sanofi Judge Skeptical She Was Wrong To Toss Antitrust Suit
• Ex-Masimo VP's 11th-Hour IP Arbitration Bid Earns Eye Roll
• Apology For 'Overheated Rhetoric' Can't Revive Patent Suit
• PTAB's Doors Would Be Closed To Generics Under Hatch Bill
• House Passes Bills On Opioid Patient Info Sharing, Treatment
• Ex-Biopharma Exec Gets 2 Years For Admitting Insider Trades
• Feds Fight Convicted Ex-Valeant Exec's Claims Of Juror Bias
• PTAB Holds Its Grounds In Post-SAS Tyvaso Review
• Allergan Denies Delaying Restasis Generic In Bid To Stop MDL
• Bard Can't Get New Trial After $3.6M Vein Filter Verdict
• BakerHostetler Nabs Brown Rudnick Corporate Partner In OC
• Mintz Levin Adds Ex-MoFo Corporate Partner In San Diego
• Bleichmar Fonti To Lead Endo Investors' Par Pharma Suit
• Tips For Keeping FDA Advisory Action Letters Out Of Court
• Life Sciences Cos. Should Assess Charitable Donations Programs
• Purdue Pharma Axes Sales Team, Lightens Focus On Opioids
• Policy Is Changing For Technology Transfers
• 10 Steps To Modernizing Corporate Integrity Agreements
• Former Aegerion Execs Say FDA Approval Negates FCA Case
• Former Akebia, Merrimack Buddies Face Insider Trading Trial
• Dental Startup Beats Big Distributors' False Ad Claims
• Drinker Biddle Adds IP Pro From Kirkland In Chicago
• #MeToo At Law Firms And What We Can Do About It
• FDA Warning Wire: Cancer Treatment Co. Slammed Again
• DOJ To Participate In Opioid MDL Settlement Talks
• AngioDynamics Seeks Biolitec Patents To Satisfy $75M Award
• Opioid Research Rules Tweaked In Bills Passed By House
• Nevro Pushes For Clarity On Expert Testimony At PTAB
• Pa. Panel Says J&J Unit Must Face Out-Of-State Plaintiffs
• High Court's Vitamin C Ruling Leaves Work For Lower Courts
• Cherokee Nation Sues Purdue Pharma Over Opioids In Okla.
• Nutraceutical Co. Must Pay $5.4M Chinese Award, Court Says
• DC Circ. Backs Boehringer In FTC Atty-Client Privilege Row
• Fed. Circ. Gives Dental Co. Shot To Amend Patent Post-Aqua
• Davis Polk Leads Roche In $2.4B Foundation Medicine Buy
• SEC Sues NY Man Over $11.5M Microcap Co. Stock Scheme
• Merck Implant Suit Barred By Wrongful Birth Law: 1st Circ.
• Abbott Escapes Ill. Suit Over Defibrillator Battery Life
• A Chat With Holland & Knight CFO Mia Stutzman
• Feds Downplay Testimony From Ex-Katten Atty's Loss Expert
• The Best Firms For Minority Equity Partners
• The Hurdles Facing BigLaw's Minority Women
• GCs Tackle Law Firm Culture In Diversity Push
• Knowledge Lawyers Can Help Firms Stay Ahead Of The Curve
• 4 Takeaways From The FDA's Info-Sharing Guidance
• PTAB Rejects Samsung Challenge To Herceptin Patent
• PE-Backed BJ's Leads 9 IPO Launches Exceeding $1.9B
• Dr. Oz Reaches $5M Settlement Over 'Miracle' Diet Pills
• In Their Own Words: Minority Partners On Reaching The Top
• Bayer Dodges Yaz, Yasmin Suit After Improper Expert Report
• CITIC Eyes $3.65B Takeover Of US-Listed China Biologic
• Ferring Will Face Counterclaims In $165M Patent Deal Row
• Lindquist Fights Nix Of Arbitration In Laser-Tech Advice Row
• Bristol-Myers Squibb: 1 Year Later
• The 2018 Law360 Diversity Snapshot
• Insights From State AG Coordinated Opioid Investigation
• Minority Lawyers On Why They Left BigLaw
• The Best Firms For Minority Attorneys
• Taking On The 'Petri Dish' Of BigLaw Bias
• Law360's Diversity Snapshot: By The Numbers
• Law360's Pro Say: What BigLaw Should Do About Diversity
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Hi-Tech Deserves $40M Sanctions, FTC Tells 11th Circ.
• Walgreens' Dual Role Helped Spur Ky. Opioid Crisis, AG Says
• PTAB Takes On Rituxan Patent, Won't Expand Follow-On Rule
• Trump Throws A Curve With Two-Pronged Tariff Approach
• 10 Firms To Steer Biotech-Heavy IPO Lineup Exceeding $1B
• Boston Scientific Wins 3rd Pelvic Mesh Verdict In Mass.
• PE-Backed Avalara Leads 3 IPOs Raising $377M Total
• Attys Reflect On Escobar's FCA Impact 2 Years Later
• Theranos Founder, Ex-COO Indicted For Fraud
• An Unprecedented Look Inside The FARA Unit
• GI Partners Nabs 2 Cos. To Form Human Tissue Storage Biz
• House OKs Tougher Rules For Illegal Drug Analogues
• Health Hires: Honigman, Arnold & Porter, GrayRobinson
• DEA Hemp Rule Is Safe For Now, But That May Change
• Options For Failing Marijuana Cos. And Their Creditors
• Trump Wallops China With Tariffs As IP Brawl Boils Over
• Drugmakers Must Face FTC's AndroGel Antitrust Suit
• USPTO Memo Cuts Mayo Woes On Treatment Method Patents
• Plaintiffs Want AbbVie Fined $500K In Testosterone Row
• Australian Device Co. Inks New Deal To Be Bought For $1.4B
• Aggrenox Buyers Slam Insurers' Bid To Opt Health Plans Out
• Ex-Pitcher Strikes Out On 3rd Swing At MLB Defamation Suit
• Texas Creates MDL For Counties' Opioid Suits
• A Farxiga Opinion That's All Hat, No Cattle
• J&J Talc Customer Paid For Risky Product, 3rd Circ. Told
• New Bill Would Bar Quick Generics Approval For PTAB Users
• Cures Revolution May Reshape Pharmaceutical Landscape
• McKesson Tries To Keep Tribal Opioid Suit In Federal Court
• Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 2
• AbbVie Wins 5th Bellwether In Testosterone MDL
• Supreme Court Says Foreign Gov't Submissions Not Binding
• J&J Gets $70M Punitives Slashed In Surgical Stapler Case
• 3rd Circ. Upholds Walgreens Victory In Doc's Defamation Case
• DEA, Media Poised For Battle Over Opioid MDL Data Access
• PTAB Shuts Down Challenge To Gilead's Hep C Drug Patents
• Ex-NJ Lab Prez, Brother Get Prison In $100M Bribery Scheme
• Muscular Dystrophy Drug Co. Seeks To Stall Derivative Suit
• Nutraceutical Appeals Enviros' Fees In Suit It Calls Moot
• 5th Circ. Rejects Pill Mill Doc's Challenge To 5-Year Sentence
• Travelers, Becton Strike Settlement In $167M Coverage Row
• Biotech Co. Pens $18.5M Deal In Investor Fraud Class Action
• California Stuck With Order Barring Glyphosate Warning
• Insys Can't Duck Investor Suit Over Opioid Spray's Financials
• Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 1
• J&J Secretly Funded Talc Study, Atty Claims
• 4th Circ. Upholds Ax Of Expert Testimony In Lipitor MDL
• NIH Unveils Research Plans To Fight Opioid Crisis
• Del. Justices Uphold $56M Award In Drug Contract Dispute
• Humana Ordered To Turn Over Docs In EpiPen Antitrust MDL
• Consultant In SEC's Illicit Stock Sale Suit Nabs Early Deal
• House Passes Policy Tweaks Targeting Opioid Abuse
• Drugmakers Denied Patient Info In Opioid MDL Bellwethers
• LabCorp Didn't Make 'Whistleblower' Break Law: Calif. Panel
• Antitrust Chief Defends Sticking To Consumer Welfare Focus
• Allergan's Fat-Freezing Unit Freed From False Ad Claims
• Pharma CEO Cops To $2M Drug Investment Fraud
• FDA Unveils Guidance On Sharing Info On Unapproved Uses
• Pet Pharma Co. Sidesteps Investor Suit Over Dog Drug Delays
• Zimmer NexGen MDL Nears Finish With Confidential Deal
• Attys Want $47M From $166M Lidoderm Pay-For-Delay Deal
• Clearer Rule On Witness Compensation Disclosure Is Needed
• Wilson Sonsini Nabs Squire Patton Tech, Life Sci Pro In LA
• Ex-Insys Execs Can't Get More Info On Charges, Feds Say
• FDA Risk-Evaluation Guidance Unlikely To Help Generics
• Alta Partners Rakes In $130M For Health Care-Focused Fund
• PTAB Invalidates Most Of Pfizer Pneumonia Vaccine Patent
• Fed. Circ. Denies Atty Fees In Kidney Device Patent Case
• Drug Cos. Unleash Opioid MDL Counterattacks
• Justices Won't Hear Cleveland Clinic Patent Eligibility Case
• Deals Rumor Mill: TPG, Stryker, Fortum
• Aggrenox MDL Nears End As Drug Cos. Reach Final Deal
• Lawmakers Seek To Hold USPS 'Accountable' In Opioid Bill
• Fed. Circ. Revives Medtronic Bid To Ax Patent In $23.5M Row
• Justices Won't Weigh Rest Break Pay, Pfizer Unit Bias Suit
• Eagle Wins Orphan Drug Status In Row With FDA
• Merck Urges Justices To Review Fosamax MDL Revival
• Mistrial Called In J&J Talc Trial After Cancer Victim Dies
• Panel Centralizes Zetia Antitrust MDL In Va.
• Ariosa Fights Sales Ban, Says It's Not An Illumina Competitor
• Plavix MDL Judge Tosses 95 Cases Due To Inaction
• Brand Battles: A 'Triple Crown' Trademark Fight
• Meet The Lobbyist Battling FDA In Epic Supplement Clash
• Par Infringed Colonoscopy Drug Patents, Fed. Circ. Affirms
• Impediments To Legal Industry's 'Inevitable' Future: Part 2
• 6 Firms To Steer 7 IPOs Exceeding $1.4B As June Gets Hot
• Philly Xarelto Patients Fight Bellwether-Manipulation Claim
• Roche, Humana Can't Flee FCA Suit Over Debt Deal
• Tennis Player Wants $10M Injury Suit Back In State Court
• Ironshore, 23andMe Get ADR OK In DNA Case Coverage Row
• PTAB Nixes Patent For Valeant's Antifungal Jublia
• Shareholder Suits Over Calif. Co.'s Roche Deal Consolidated
• Blocking Patent Focus Of Acorda's Fed. Circ. MS Drug Appeal
• FTC Says Patent Infringement Suits Are Not Antitrust Proof
• UK Tribunal Overturns £89M Epilepsy Drug Pricing Fine
• Biogen, Drugmaker Settle Angiomax Patent Royalties Row
• Schlichtmann Must Face Avandia Settlement Malpractice Row
• Impediments To Legal Industry's 'Inevitable' Future: Part 1
• Drug Co. Lundbeck To Settle Charity Support Probe For $52M
• Walgreen, Kroger Join J&J's Remicade Antitrust Brawl
• Latest J&J Talc Trial Pits Co. Against 22 Women
• SEC Says BioChemics Is Unable To Pay $17M Bill To Investors
• Convicted Valeant Exec Says Dishonest Juror Tainted Trial
• Reseller Not Enough To Keep Medical Device IP Row In Texas
• Deals Rumor Mill: PetSmart, Azelis, BHP
• Fortive Offers $2.7B To Acquire J&J Medical Products Unit
• Alston Picks Up Ex-Drinker Biddle Product Liability Partner
• King & Spalding Nabs International Arbitration Pro In Paris
• Genentech Wants White & Case To Share Samsung Drug Info
• Calif. Court Affirms State Rule For Lead Discharge Levels
• Fosamax Users Urge High Court To Turn Down Merck Appeal
• LabCorp Slams Claims It Conspired To Block Del. Startup
• J&J Battles To Throw Out $117M Verdicts In NJ Talc Case
• Supplement Maker Can't Prove Consent Judgment Violated
• Gov't Keeps FCA Claims Against Sleep-Testing Co. Alive
• FCPA Enforcement Activity In Early 2018: Part 2
• 7 Common Mistakes In Company Witness Prep
• Pfizer's Investment Arm Snags $600M With Eye On Biotechs
• AbbVie Wore 'Blinders' On AndroGel's Clot Risk, Jury Told
• Hard Hit By Opioids, Tribes To Get Own Track Within MDL
• VC-Backed Verrica Pharmaceuticals Joins June IPO Parade
• Don't Revive Opioid Patents, Generics Maker Tells Fed. Circ.
• 3rd Circ. Revives Suit Of Nurse Fired After Vaccine Refusal
• Viveve, Thermi Settle Suit Over Vagina Reshaping Patent
• FDA Warning Wire: Online Opioid Sales, Caffeine Crackdown
• SEC Probe Into Biotech Co. Made Shares Drop, Investor Says
• Deals Rumor Mill: Abu Dhabi National Oil, Recordati, Abraaj
• Zydus Defends Antitrust Claims In Prevacid Patent Suit
• Dynavax Hepatitis Vaccine Shareholder Suit Tossed Again
• FCPA Enforcement Activity In Early 2018: Part 1
• Class Counsel To Collect Over $6M In Akorn Accounting Row
• Moving Toward A Standard Of Care For Medical Marijuana
• Deal OK Sought In OvaScience Director Compensation Suit
• How New Testimonial Evidence Affects IPR Institution
• Investors Denied Default $11.1M Award In Tibet Pharma Suit
• Filmmaker Takes 2nd Crack At Theranos Deposition Footage
• Humana, Drug Cos. Settle In Aggrenox Pay-For-Delay Row
• Fed. Circ. Weighs Immunity From IPR In Tribal IP Transfer
• Express Scripts, CVS Want EpiPen Cost ERISA Suit Tossed
• FDA Says 5 More Deaths Tied To Obesity Stomach Balloons
• PTAB Interpreting SAS Too Broadly, Knee Implant Co. Says
• End-Payor Attys Want $16M From $43M Medicis, Impax Deals
• Pfizer Unit Used Partnership To Cut Rival's Supply, Suit Says
• Regeneron Urges Justices To Ax Inequitable Conduct Ruling
• Medicaid Groups' Atty Seeks Spot On Opioid Exec Committee
• Atty's 17 Years For Stock Scheme Was Proper, Feds Say
• Fenwick & West Nabs Technology Exec Compensation Partner
• Clinic Says Patent Eligibility 'Begs' For High Court Help
• Fed. Circ. Weighs In On Obviousness-Type Double Patenting
• Allergy Tester Wants Baker Donelson DQ'd From Antitrust Suit
• FDA Drug Review Office Plans Overhaul To Boost Efficiency
• 7th Circ. Says Expert Necessary To Sue Teva Over Broken IUD
• Why Widespread Use Of Live Video Testimony Is Not Justified
• Tech 'Unicorn' Domo Among 6 Cos. Filing IPO Plans
• Drinker Biddle Adds Ex-Dentons Trade Secrets Leader
• Momenta, Sandoz Denied Mid-Suit Antitrust Claims Appeal
• Charity Sues Insurer To Cover Calif. DOJ's False Ad Suit
• Shkreli Deals Saved Retrophin Millions, Ex-Katten Atty Argues
• Tribal Immunity At The Fed. Circ.: What You Need To Know
• Cooley Nabs Katten Litigator For Securities Practice
• HHS To Delay Drug Pricing Rule To July 2019
• Theranos Indirect Investors Denied Class Cert. For Fraud Suit
• Merck Shareholder's Doc Request Too Broad, NJ Court Says
• A Peek Into The World Of NAD Director Laura Brett
• Seneca Nation Says Pharma Cos. At Fault For Opioid Crisis
• Judging A Book: Wallach Reviews 'Uncivil Warriors'
• Health Hires: K&L Gates, Womble Bond, Bellicum Pharma
• A Closer Look At New Federal 'Right To Try' Law